From Wikipedia, the free encyclopedia
Chemical compound
Luvadaxistat is an experimental drug that works as a
D-amino acid oxidase inhibitor and is supposed to increase
NMDA receptor functionality.
[1] It is developed to treat
Friedrich ataxia
[2] and negative symptoms of
schizophrenia .
[3]
[4]
[5]
References
^ O’Donnell, Patricio; Dong, Cheng; Murthy, Venkatesha; Asgharnejad, Mahnaz; Du, Xiaoming; Summerfelt, Ann; Lu, Hong; Xu, Lin; Wendland, Jens R.; Dunayevich, Eduardo; Buhl, Derek L.; Litman, Robert; Hetrick, William P.; Hong, L. Elliot; Rosen, Laura B. (June 2023).
"The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial" . Neuropsychopharmacology . 48 (7): 1052–1059.
doi :
10.1038/s41386-023-01560-0 .
ISSN
1740-634X .
PMC
10018616 .
PMID
36928351 .
^ Wang, Hao; Norton, Jonathan; Xu, Lin; DeMartinis, Nicholas; Sen, Rohini; Shah, Ankit; Farmer, Jennifer; Lynch, David (June 2021).
"Results of a randomized double‐blind study evaluating luvadaxistat in adults with Friedreich ataxia" . Annals of Clinical and Translational Neurology . 8 (6): 1343–1352.
doi :
10.1002/acn3.51373 .
PMC
8164851 .
PMID
34018342 .
^ Fradley, Rosa; Goetghebeur, Pascal; Miller, David; Burley, Russell; Almond, Sarah; Gruart i Massó, Agnès; Delgado García, José M.; Zhu, Bin; Howley, Eimear; Neill, Jo C.; Grayson, Ben; Gaskin, Philip; Carlton, Mark; Gray, Ian; Serrats, Jordi; Davies, Ceri H. (October 2023).
"Luvadaxistat: A Novel Potent and Selective d-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia" . Neurochemical Research . 48 (10): 3027–3041.
doi :
10.1007/s11064-023-03956-2 .
PMC
10471729 .
PMID
37289348 .
^ Veselinović, Tanja; Neuner, Irene (August 2022).
"Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia" . CNS Drugs . 36 (8): 819–858.
doi :
10.1007/s40263-022-00935-z .
PMC
9345797 .
PMID
35831706 .
^ Kuo, Chien-Yi; Lin, Chieh-Hsin; Lane, Hsien-Yuan (November 2022). "Targeting d-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research". CNS Drugs . 36 (11): 1143–1153.
doi :
10.1007/s40263-022-00959-5 .
PMID
36194364 .
S2CID
252694226 .